FOLH1 and prostate carcinoma: Based upon the PSMA overexpression on prostate cancer cells’ membrane, radiopharmaceuticals targeting this receptor became a relatively novel compound to improve the performance of molecular imaging and to develop new therapeutic instruments through radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (although it does not substitute for laboratory examinations and MRI in its diagnosis).